METASTATIC GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA
Clinical trials for METASTATIC GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New triple therapy aims to extend life in Hard-to-Treat stomach cancers
Disease control Recruiting nowThis study tests whether adding zolbetuximab to standard immunotherapy (pembrolizumab) and chemotherapy helps people with advanced stomach or gastroesophageal junction cancer live longer. About 500 adults whose tumors have specific markers (CLDN18.2-positive, PD-L1-positive, HER2…
Matched conditions: METASTATIC GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated May 26, 2026 05:00 UTC
-
New drug VYLOY under Real-World watch for stomach cancer safety
Disease control Recruiting nowThis study monitors the safety of the drug VYLOY in 377 people in South Korea with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread. Participants receive VYLOY as part of their normal care, and researchers track side effects and…
Matched conditions: METASTATIC GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA
Sponsor: Astellas Pharma Korea, Inc. • Aim: Disease control
Last updated May 26, 2026 04:38 UTC
-
New hope for stomach cancer: early access drug targets tough tumors
Disease control AVAILABLEThis program offers early access to zolbetuximab, a targeted therapy, for people with advanced stomach or gastroesophageal junction cancer that has a specific protein (CLDN18.2) and is not HER2-positive. Participants receive zolbetuximab alongside standard chemotherapy to help co…
Matched conditions: METASTATIC GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA
Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated May 22, 2026 14:03 UTC